News Column

New Findings on Neoplasms Described by Investigators at Institute for Medical Biometry (Prognostic Stratification of Metastatic...

September 5, 2014



New Findings on Neoplasms Described by Investigators at Institute for Medical Biometry (Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by F-18-FDG PET: Feasibility of a Metabolic Grading System)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Neoplasms. According to news reporting out of Bonn, Germany, by NewsRx editors, research stated, "The tumor proliferation marker, Ki-67 index, is a well-established prognostic marker in gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging allows whole-body metabolic characterization of metastatic disease."

Our news journalists obtained a quote from the research from Institute for Medical Biometry, "We investigated the prognostic impact of F-18-FDG PET in inoperable multifocal disease. Retrospective, dual-center analysis was performed on 89 patients with histologically confirmed, inoperable metastatic gastroenteropancreatic NENs undergoing F-18-FDG PET/CT within the staging routine. Metabolic (PET-based) grading was in accordance with the most prominent F-18-FDG uptake (reference tumor lesion): mG1, tumor-to-liver ratio of maximum standardized uptake value 1.0; mG2, 1.0-2.3; mG3, >2.3. Other potential variables influencing overall survival, including age, tumor origin, performance status, tumor burden, plasma chromogranin A (>= 600 mu g/L), neuronspecific enolase (>= 25 mu g/L), and classic grading (Ki-67-based) underwent univariate (log-rank test) and multivariate analysis (Cox proportional hazards model), with a P value of less than 0.05 considered significant. The median follow-up period was 38 mo (95% confidence interval [CI], 27-49 mo); median overall survival of the 89 patients left for multivariate analysis was 29 mo (95% CI, 21-37 mo). According to metabolic grading, 9 patients (10.2%) had mG1 tumors, 22 (25.0%) mG2, and 57 (64.8%) mG3. On multivariate analysis, markedly elevated plasma neuron-specific enolase (P = 0.016; hazard ratio, 2.9; 95% CI, 1.2-7.0) and high metabolic grade (P = 0.015; hazard ratio, 4.7; 95% CI, 1.2-7.0) were independent predictors of survival."

According to the news editors, the research concluded: "This study demonstrated the feasibility of prognostic 3-grade stratification of metastatic gastroenteropancreatic NENs by whole-body molecular imaging using F-18-FDG PET."

For more information on this research see: Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by F-18-FDG PET: Feasibility of a Metabolic Grading System. Journal of Nuclear Medicine, 2014;55(8):1260-1266. Journal of Nuclear Medicine can be contacted at: Soc Nuclear Medicine Inc, 1850 Samuel Morse Dr, Reston, VA 20190-5316, USA (see also Neoplasms).

Our news journalists report that additional information may be obtained by contacting S. Ezziddin, Inst Med Biometry Informat & Epidemiol, Bonn, Germany. Additional authors for this research include L. Adler, A. Sabet, T.D. Poppel, F. Grabellus, A. Yuce, H.P. Fischer, B. Simon, T. Holler, H.J. Biersack and J. Nagarajah.

Keywords for this news article include: Bonn, Europe, Germany, Enolase, Neoplasms, Nanotechnology, Molecular Imaging, Emerging Technologies, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters